Ulsan, South Korea – A groundbreaking technology with immense potential in treating ischemic retinopathy in premature infants and diabetic patients has been developed by Professor Byoung Heon Kang and his research team in the Department of Biological Sciences at UNIST, in collaboration with Professor Dong Ho Park’s team at Kyungpook...
Latest News
Bosto, Mass. – A major breakthrough in the treatment of amyotrophic lateral sclerosis, known as ALS, can potentially help stop the disease in its tracks in as much as half of the cases in the U.S., a Northeastern University scientist says. Jeffrey Agar, associate professor of chemistry and pharmaceutical sciences...
San Diego, Calif. – Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. BAY 2927088 is...
Orlando, Florida – University of Central Florida College of Medicine researcher Renee Fleeman is on a mission to kill drug-resistant bacteria, and her latest study has identified a therapy that can penetrate the slime that such infections use to protect themselves from antibiotics. In a study published recently in Cell Reports...
Milan, Italy: Patients with breast cancer that has started to spread to the lymph nodes in the armpit can safely avoid extensive removal of the lymph nodes if their treatment is tailored to their response to cancer-killing therapies such as chemotherapy before surgery. In a presentation to the 14th European...
Brentuximab vedotin produces durable responses and prolongs progression-free survival (PFS), when compared with physician’s choice of therapy, in previously treated patients with CD30-expressing cutaneous T-cell lymphoma (CTCL), according to final results from the ALCANZA study published in Blood Advances. The phase 3 ALCANZA trial (ClinicalTrials.gov Identifier: NCT01578499) enrolled 131 patients with mycosis...
Brentuximab vedotin produces durable responses and prolongs progression-free survival (PFS), when compared with physician’s choice of therapy, in previously treated patients with CD30-expressing cutaneous T-cell lymphoma (CTCL), according to final results from the ALCANZA study published in Blood Advances. The phase 3 ALCANZA trial (ClinicalTrials.gov Identifier: NCT01578499) enrolled 131 patients with mycosis...
SEONGNAM, South Korea and NEWTON, Mass — Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the company has initiated the Phase 1/2 clinical trial evaluating the safety, tolerability, and antitumor activity of BBT-207 in non-small cell lung cancer (NSCLC)...
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for acoramidis, an investigational drug for the treatment of ATTR-CM. The...
PALO ALTO, Calif. and BERLIN, Germany — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and Bayer today announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. In exchange, BridgeBio will receive up to $310 million USD comprising of upfront and near-term milestone payments,...